Gossamer Bio Submits First NDA for Seralutinib in PAH
GOSS sits 23% above its 52-week low of $9.104.
Summary
Gossamer Bio submitted its first NDA to the FDA for seralutinib in PAH, supported by Phase 3 PROSERA and Phase 2 TORREY data. FDA filing acceptance is anticipated later this year.
Key Events · Product Development and Regulatory · GOSS
-
First NDA Submitted
In September 2026, the company submitted its first New Drug Application to the FDA for seralutinib in pulmonary arterial hypertension.
-
Regulatory De-Risking
FDA Pre-NDA Type B meeting minutes characterized PROSERA statistical significance and treatment effect magnitude as review issues rather than filing issues.
-
Filing Acceptance Timeline
Following initial review, the FDA will determine whether to accept the NDA for filing, a decision the company anticipates could occur later this year.
-
Survival Context
The NDA submission is critical for a company with a going-concern warning and Nasdaq delisting risk disclosed in its August 2026 10-Q.
Analysis · GOSS · Life Sciences
A pivotal regulatory milestone has been reached: Gossamer Bio has submitted its first New Drug Application to the FDA for seralutinib in pulmonary arterial hypertension. The filing is backed by the Phase 3 PROSERA study and Phase 2 TORREY data, and the FDA's pre-NDA meeting minutes framed the key efficacy questions as review issues rather than filing issues — a meaningful de-risking signal. FDA acceptance for filing is expected later this year. This is a pivotal regulatory milestone for a company whose entire future depends on seralutinib, especially given the going-concern warning and Nasdaq delisting risk disclosed in August.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOSS was trading at $11.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.2M. The 52-week trading range was $9.10 to $309.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.